Evaluation of Correlation of Ki-67 Factor in Prostate Cancer with Apparent Diffusion Coefficient Index in Multi b-value Diffusion Magnetic Resonance Imaging

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Medical Imaging, School of Medicine, Isfahan University of Medical Sciences Isfahan AND Radiotechnologist, Department of Radiology, Amiralmomenin Hospital, Shahreza, Iran

2 Professor, Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Isfahan Kidney Transplantation Research Center AND Department of Urology, Alzahra Research Centers, Isfahan University of Medical Sciences, Isfahan, Iran

4 Assistant Professor, Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 Radiologist, Department of Imaging, Askarieh Hospital, Isfahan, Iran

Abstract

Background: Recent advances in molecular imaging of prostate cancer, including diffusion-weighted imaging, have led to improved cancer screening methods. The Ki-67 biomarker plays an important role in the prevention, diagnosis, and treatment of prostate cancer. The purpose of this study was to investigate the correlation between apparent diffusion coefficient of diffusion weight imaging with Ki-67 factor.Methods: This was a cross-sectional study on 36 patients with prostate cancer, who underwent radical prostatectomy. All patients underwent diffusion weight imaging before surgery, and Ki-67 factor was evaluated by immunohistochemistry (IHC). Statistical analysis was performed to investigate the relationship between apparent diffusion coefficient and Ki-67 factor using SPSS software.Findings: The ki-67 factor was inversely correlated with the apparent diffusion coefficient in peripheral (P < 0.001) and interstitial zone (P = 0.030). Nevertheless, it had a direct relationship with the degree of tumor malignancy (P = 0.035).Conclusion: Apparent diffusion coefficient can be used as a noninvasive criterion for assessing ki-67 and prostate cancer tumor invasion, which is important in diagnosing, grading, and predicting the survival of patients with prostate cancer.

References

  1. Kasivisvanathan V, Arya M, Ahmed HU, Moore CM, Emberton M. A randomized controlled trial to investigate magnetic resonance imaging-targeted biopsy as an alternative diagnostic strategy to transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. Urol Oncol 2015; 33(3): 156-7.
  2. Walsh AL, Considine SW, Thomas AZ, Lynch TH, Manecksha RP. Digital rectal examination in primary care is important for early detection of prostate cancer: a retrospective cohort analysis study. Br J Gen Pract 2014; 64(629): e783-e787.
  3. Kam SC, Choi SM, Yoon S, Choi JH, Lee SH, Hwa JS, et al. Complications of transrectal ultrasound-guided prostate biopsy: impact of prebiopsy enema. Korean J Urol 2014; 55(11): 732-6.
  4. Pollack A, Paryani SB, Hussey D, Perez CA, Beyer DC, Blasko JC, et al. Locally advanced (high-risk) prostate cancer. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000; 215(Suppl): 1401-12.
  5. White NS, McDonald C, Farid N, Kuperman J, Karow D, Schenker-Ahmed NM, et al. Erratum: Diffusion-Weighted imaging in cancer: Physical foundations and applications of restriction spectrum imaging (Cancer Research (2014) 74 (4638-4652)). Cancer Res 2014; 74(22): 6733.
  6. Cuocolo R, Stanzione A, Rusconi G, Petretta M, Ponsiglione A, Fusco F, et al. PSA-density does not improve bi-parametric prostate MR detection of prostate cancer in a biopsy naive patient population. Eur J Radiol 2018; 104: 64-70.
  7. Ueno Y, Kitajima K, Sugimura K, Kawakami F, Miyake H, Obara M, et al. Ultra-high b-value diffusion-weighted MRI for the detection of prostate cancer with 3-T MRI. J Magn Reson Imaging 2013; 38(1): 154-60.
  8. Tuffaha MSA, Guski H, Kristiansen G. Markers to assist the diagnosis of dysplasia and malignant transformation. In: Tuffaha MSA, Guski H, Kristiansen G, editors. Immunohistochemistry in tumor diagnostics. Cham, Switzerland: Springer International Publishing; 2018. p. 253-5.
  9. Aaltomaa S, Lipponen P, Vesalainen S, Ala-Opas M, Eskelinen M, Syrjanen K. Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. Eur Urol 1997; 32(4): 410-5.
  10. Spratt DE. Ki-67 remains solely a prognostic biomarker in localized prostate cancer. Int J Radiat Oncol Biol Phys 2018; 101(3): 513-5.
  11. Ma T, Yang S, Jing H, Cong L, Cao Z, Liu Z, et al. Apparent diffusion coefficients in prostate cancer: correlation with molecular markers Ki-67, HIF-1alpha and VEGF. NMR Biomed 2018; 31(3).
  12. Zhang J, Jing H, Han X, Huang Z, Cao Z, Liu Q. Diffusion-weighted imaging of prostate cancer on 3T MR: Relationship between apparent diffusion coefficient values and Ki-67 expression. Acad Radiol 2013; 20(12): 1535-41.
  13. Mesko S, Kupelian P, Demanes DJ, Huang J, Wang PC, Kamrava M. Quantifying the ki-67 heterogeneity profile in prostate cancer. Prostate Cancer 2013; 2013: 717080.
  14. Onishi N, Kanao S, Kataoka M, Iima M, Sakaguchi R, Kawai M, et al. Apparent diffusion coefficient as a potential surrogate marker for Ki-67 index in mucinous breast carcinoma. J Magn Reson Imaging 2015; 41(3): 610-5.
  15. Surov A, Ginat DT, Sanverdi E, Lim CCT, Hakyemez B, Yogi A, et al. Use of diffusion weighted imaging in differentiating between maligant and benign meningiomas. A multicenter analysis. World Neurosurg 2016; 88: 598-602.
  16. Sun Y, Tong T, Cai S, Bi R, Xin C, Gu Y. Apparent Diffusion Coefficient (ADC) value: A potential imaging biomarker that reflects the biological features of rectal cancer. PLoS One 2014; 9(10): e109371.
Journal of Isfahan Medical School
Volume 37, Issue 547 - Serial Number 547
September and October 2020
Pages 1162-1168

Files

History

  • Receive Date: 30 September 2019
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics